SCHEMBL6496758

SCHEMBL6496758

O=C(c1ccc(Cl)cc1)N1CCCN(Cc2cccc(Oc3ccccc3)c2)CC1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.78
ALDH1A1 P00352 3/20 0.78
KDM4E B2RXH2 2/20 0.78
SMN1; SMN2 Q16637 2/20 0.78
GAA P10253 1/20 0.78
CCR8 P51685 4/20 0.76
KCNH2 Q12809 4/20 0.76
FAAH O00519 8/20 0.66
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
MAPT P10636 1/20 0.61
RECQL P46063 1/20 0.61
TSHR P16473 1/20 0.57
MAPK1 P28482 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500733 0.90 KDM4E (0.78) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6503708 0.88 CCR8 (0.79) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL5431975 0.84 CCR8 (0.87) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL3355088 0.83 FAAH (0.74) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL13149349 0.83 KDM4E (0.78) LMNAALDH1A1KDM4ESMN1; SMN2MEN1
SCHEMBL12540343 0.81 ALDH1A1 (0.78) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL12332155 0.80 FAAH (0.70) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6498313 0.80 ALDH1A1 (0.65) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL6509473 0.80 KDM4E (0.65) LMNAALDH1A1KDM4ESMN1; SMN2GAA
SCHEMBL30302091 0.80 KDM4E (0.75) LMNAALDH1A1KDM4ESMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2005-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143372-A1 Compounds, pharmaceutical compositions and methods of use therefor CCR8, CCL11, CCR5 LMNA 4603/4885ALDH1A1 1071/4885KDM4E 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.